RhumbLine Advisers
MREO

RhumbLine Advisers’s Mereo BioPharma MREO Stock Holding History

RhumbLine Advisers’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.45K Buy
19,572
+426
+2% +$183 ﹤0.01% 3852
2025
Q4 		$7.98K Buy
19,146
+10,024
+110% +$19.1K ﹤0.01% 3882
2025
Q3 		$18.8K Sell
9,122
-756
-8% -$1.39K ﹤0.01% 3787
2025
Q2 		$26.8K Buy
9,878
+3,290
+50% +$7.94K ﹤0.01% 3766
2025
Q1 		$14.8K Sell
6,588
-649
-9% -$1.84K ﹤0.01% 3779
2024
Q4 		$25.3K Sell
7,237
-36
-0.5% -$141 ﹤0.01% 3771
2024
Q3 		$29.9K Buy
7,273
+315
+5% +$1.3K ﹤0.01% 3759
2024
Q2 		$25K Buy
6,958
+2,887
+71% +$9.35K ﹤0.01% 3831
2024
Q1 		$13.4K Buy
4,071
+162
+4% +$548 ﹤0.01% 3821
2023
Q4 		$9.03K Buy
3,909
+311
+9% +$595 ﹤0.01% 3882
2023
Q3 		$4.64K Buy
3,598
+340
+10% +$451 ﹤0.01% 3992
2023
Q2 		$4.3K Buy
+3,258
New +$3.78K ﹤0.01% 4116

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

RhumbLine Advisers's MREO Position: Q1 2026 in Review

RhumbLine Advisers increased its Mereo BioPharma (MREO) stake by 2.2% in Q1 2026, buying an estimated $183 and bringing the position to 19,572 shares worth $6.45K. The position accounts for ﹤0.01% of the portfolio, ranked #3852.

RhumbLine Advisers first reported a position in MREO in Q2 2023 and has held it in 12 quarters since. The position peaked at $29.9K in Q3 2024. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • RhumbLine Advisers held 19,572 shares of Mereo BioPharma worth $6.45K as of Q1 2026.
  • RhumbLine Advisers bought 426 Mereo BioPharma shares in Q1 2026, an estimated $183.
  • Mereo BioPharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3852 holding.
  • RhumbLine Advisers first reported a position in Mereo BioPharma in Q2 2023 and has held it in 12 quarters since.
  • RhumbLine Advisers's Mereo BioPharma position peaked at $29.9K in Q3 2024.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.